Authors : Abhishek Ranjan, Abhishek Ranjan, Satapathy K Sugyani, Satapathy K Sugyani, Mukta Prasad, Mukta Prasad
DOI : 10.18231/j.ijooo.2021.037
Volume : 7
Issue : 2
Year : 2021
Page No : 190-194
Background: Glaucoma is progressive optical neuropathy which is challenging to treat despite advances in medical and interventional mode of treatments. Primary open angle glaucoma(POAG) is generally associated with diabetes mellitus and hypertension. Any ocular topical pharmacological agent which is to be used in POAG to maintain intraocular pressure have to be very efficacious with good safety profile. We conducted a study comparing travoprost with latanoprost and timolol as single therapeutic agent having favorable outcome.
Materials and Methods: Seventy five patients were included in the study for a period of two years. After ethical clearance, patients were randomly allocated to three groups of treatment arm having 25 patients in each group. IOP was noted at 8 A.M, 10 A.M, 4 P.M on two eligibility visits for the same eye. Data collected included demographic data, blood pressure, visual acuity, ocular hyperaemia, Slit lamp finding, IOP & fundus examination.
Result: Travoprost treated patients had minimum IOP significantly lower at all visits than those using timolol (p<0>
Conclusion: TRAVOPROST 0.004% once daily or in combination with other agents is the most effective and safest topical agents for patients of primary open angle glaucoma with the best safety profile.
Keywords: (MeSH) prostaglandin analogue, IOP, Ocular hyperaemia, Diurnal variations.